Literature DB >> 3100118

Agglutination of intravenous lipid emulsion ('Intralipid') and plasma lipoproteins by C-reactive protein.

I R Rowe, A K Soutar, M B Pepys.   

Abstract

Isolated human C-reactive protein (CRP), or CRP in acute phase serum, produced in-vitro agglutination ('creaming') of the intravenously administered lipid suspension 'Intralipid'. CRP also produced similar agglutination of isolated normal very low density lipoproteins (VLDL). Agglutination in both cases was calcium-dependent and inhibitable by phosphoryl choline. These findings have important implications for patients receiving intravenous lipid suspensions and may be relevant to the pathogenesis of the fat embolism syndrome following trauma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3100118      PMCID: PMC1542672     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  The fat embolism syndrome.

Authors:  A R Gurd; R I Wilson
Journal:  J Bone Joint Surg Br       Date:  1974-08

2.  Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide.

Authors:  J E Volanakis; M H Kaplan
Journal:  Proc Soc Exp Biol Med       Date:  1971-02

3.  Enzymatic determination of total serum cholesterol.

Authors:  C C Allain; L S Poon; C S Chan; W Richmond; P C Fu
Journal:  Clin Chem       Date:  1974-04       Impact factor: 8.327

4.  Comparative studies on the binding properties of human and rabbit C-reactive proteins.

Authors:  E B Oliveira; E C Gotschlich; T Y Liu
Journal:  J Immunol       Date:  1980-03       Impact factor: 5.422

5.  Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin.

Authors:  M H Kaplan; J E Volanakis
Journal:  J Immunol       Date:  1974-06       Impact factor: 5.422

6.  A new clinical and experimental concept on fat embolism.

Authors:  P Fuchsig; P Brücke; G Blümel; R Gottlob
Journal:  N Engl J Med       Date:  1967-05-25       Impact factor: 91.245

7.  Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction.

Authors:  I Kushner; M L Broder; D Karp
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

8.  Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum.

Authors:  M B Pepys; A C Dash; R E Markham; H C Thomas; B D Williams; A Petrie
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

9.  Lipoprotein changes after burn injury in man.

Authors:  E J Coombes; P G Shakespeare; G F Batstone
Journal:  J Trauma       Date:  1980-11

10.  Rabbit and rat C-reactive proteins bind apolipoprotein B-containing lipoproteins.

Authors:  I F Rowe; A K Soutar; I M Trayner; M L Baltz; F C de Beer; L Walker; D Bowyer; J Herbert; A Feinstein; M B Pepys
Journal:  J Exp Med       Date:  1984-02-01       Impact factor: 14.307

View more
  4 in total

1.  Pulmonary intravascular lipid in neonatal necropsy specimens.

Authors:  J W Puntis; D I Rushton
Journal:  Arch Dis Child       Date:  1991-01       Impact factor: 3.791

2.  Cryo-Electron Microscopy and Biochemical Analysis Offer Insights Into the Effects of Acidic pH, Such as Occur During Acidosis, on the Complement Binding Properties of C-Reactive Protein.

Authors:  Dylan P Noone; Tijn T van der Velden; Thomas H Sharp
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

Review 3.  Relevance of lipoproteins, membranes, and extracellular vesicles in understanding C-reactive protein biochemical structure and biological activities.

Authors:  Lawrence A Potempa; Wei Qiao Qiu; Ashley Stefanski; Ibraheem M Rajab
Journal:  Front Cardiovasc Med       Date:  2022-09-08

Review 4.  An overview on human serum lectins.

Authors:  S Beulaja Manikandan; R Manikandan; M Arumugam; P Mullainadhan
Journal:  Heliyon       Date:  2020-08-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.